368 related articles for article (PubMed ID: 33886088)
1. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients.
Cheng HR; Yang HC; Lin SR; Yang TY; Lin YY; Su TH; Tseng TC; Liu CJ; Kao JH
Hepatol Int; 2021 Jun; 15(3):582-592. PubMed ID: 33886088
[TBL] [Abstract][Full Text] [Related]
2. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
[TBL] [Abstract][Full Text] [Related]
3. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
[TBL] [Abstract][Full Text] [Related]
4. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
Papatheodoridi M; Papachristou E; Moschidis Z; Hadziyannis E; Rigopoulou E; Zachou K; Villeret F; Magiorkinis G; Lyberopoulou A; Gatselis N; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Paraskevis D; Papatheodoridis GV
J Viral Hepat; 2022 Nov; 29(11):948-957. PubMed ID: 35789515
[TBL] [Abstract][Full Text] [Related]
5. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
Huang PY; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
J Viral Hepat; 2021 Aug; 28(8):1141-1149. PubMed ID: 33932245
[TBL] [Abstract][Full Text] [Related]
6. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
Tseng TN; Jeng WJ; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
J Antimicrob Chemother; 2023 Feb; 78(2):436-439. PubMed ID: 36478233
[TBL] [Abstract][Full Text] [Related]
7. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
[TBL] [Abstract][Full Text] [Related]
8. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation.
Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Huang Y; Nan Y; Zheng H; Feng B
J Gastroenterol; 2021 Sep; 56(9):856-867. PubMed ID: 34292372
[TBL] [Abstract][Full Text] [Related]
9. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B.
Mak LY; Wong D; Kuchta A; Hilfiker M; Hamilton A; Chow N; Mao X; Seto WK; Yuen MF
Clin Mol Hepatol; 2023 Jan; 29(1):146-162. PubMed ID: 35989092
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation.
Tsai YN; Wu JL; Tseng CH; Chen TH; Wu YL; Chen CC; Fang YJ; Yang TH; Nguyen MH; Lin JT; Hsu YC
Clin Mol Hepatol; 2024 Jan; 30(1):98-108. PubMed ID: 38092551
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
13. Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment.
Sandmann L; Bremer B; Ohlendorf V; Jaroszewicz J; Wedemeyer H; Cornberg M; Maasoumy B
Viruses; 2024 Feb; 16(2):. PubMed ID: 38400031
[TBL] [Abstract][Full Text] [Related]
14. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients.
Kim YJ; Kim K; Hwang SH; Kim SS; Lee D; Cheong JY; Cho SW
Clin Mol Hepatol; 2013 Sep; 19(3):300-4. PubMed ID: 24133668
[TBL] [Abstract][Full Text] [Related]
15. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
[TBL] [Abstract][Full Text] [Related]
16. Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic hepatitis B patients.
Chen L; Gan QR; Zhang DQ; Yao LF; Lin RS; Li Q; Lin MH; Yu DM; Zhang XX; Pan C
Clin Microbiol Infect; 2016 Feb; 22(2):201-207. PubMed ID: 26493847
[TBL] [Abstract][Full Text] [Related]
17. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis.
Liu Y; Jia M; Wu S; Jiang W; Feng Y
Int J Infect Dis; 2019 Sep; 86():201-207. PubMed ID: 31394205
[TBL] [Abstract][Full Text] [Related]
18. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B.
Song DS; Jang JW; Yoo SH; Kwon JH; Nam SW; Bae SH; Choi JY; Yoon SK
Clin Infect Dis; 2021 Aug; 73(4):e892-e903. PubMed ID: 33417679
[TBL] [Abstract][Full Text] [Related]
19. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status.
Liu F; Liu ZR; Li T; Liu Y; Zhang M; Xue Y; Zhang LX; Ye Q; Fan XP; Wang L
J Dig Dis; 2018 Sep; 19(9):561-571. PubMed ID: 30098114
[TBL] [Abstract][Full Text] [Related]
20. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
